RRMS Clinical Study of New Antibiotic Therapy Nearing End

Stuart SchlossmanMS Research Study and Reports

First data from Phase 2a study of RedHill Biopharma’s RHB-104 expected in early 2016
RedHill
Biopharma, Ltd., recently announced the conclusion of the last dosing and
patient follow-up visit for its Phase 2a proof-of-concept study to assess the
efficacy and safety of the experimental drug RHB-104 as an add-on therapy to
interferon beta-1a in patients with relapsing-remitting multiple sclerosis
(RRMS). MS is a demyelinating disease in which the insulating covers […]

Read on »

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews